Non-Protein Coding RNA 185 (NCRNA00185) as a Drug Target and Biomarker

Target Name: Non-protein coding RNA 185

NCBI ID: G55410

Non-protein coding RNA 185

Other Name(s): NCRNA00185 | CYorf14 | PRO2834

Non-Protein Coding RNA 185 (NCRNA00185) as a Drug Target and Biomarker

Non-protein coding RNAs (ncRNAs) have emerged as a promising source of new biomarkers and drug targets in recent years. These small non-coding RNAs play a crucial role in gene regulation, tissue development, and various biological processes. One of the most promising and widely studied ncRNAs is Non-Protein Coding RNA 185 (NCRNA00185). NCRNA00185 is a non-coding RNA molecule that has been identified using RNA sequencing (RNA-seq) and other bioinformatics tools. In this article, we will discuss the potential implications of NCRNA00185 as a drug target and biomarker.

Drug Target Potential

NCRNA00185 is a potential drug target due to its unique structure and biology. Ncrna00185 is a small RNA molecule that contains 185 nucleotides. It is composed of a single exon and a single intron, which means that it is a single RNA molecule but has a unique structure. Ncrna00185 has a characteristic stem-loop structure that is composed of a series of alternating double-stranded regions and a single single-stranded region. This unique structure allows Ncrna00185 to have a stable secondary structure, which is important for maintaining the stability and stability of RNA molecules.

Ncrna00185 has been shown to play a role in various biological processes, including cell growth, apoptosis, and inflammation. Many studies have demonstrated that Ncrna00185 is involved in the regulation of cell growth and cell cycle progression. Ncrna00185 has also been shown to play a role in apoptosis, which is the process by which cells die. Ncrna00185 has been shown to be involved in the regulation of apoptosis-related genes, including Bcl-2 and p53.

In addition to its role in apoptosis, Ncrna00185 has also been shown to be involved in the regulation of cell signaling pathways. Ncrna00185 has been shown to play a role in the regulation of TGF-β signaling pathway, which is a critical pathway involved in cell growth, differentiation, and inflammation.

Biomarker Potential

NCRNA00185 has also been shown to have potential as a biomarker for various diseases, including cancer, neurodegenerative diseases, and autoimmune diseases. Ncrna00185 has been shown to be involved in the regulation of gene expression in various diseases, including cancer. Ncrna00185 has been shown to play a role in the regulation of cancer-related genes, including p53, Bcr/Abl, and Tgf-1b.

In addition to its role in cancer, Ncrna00185 has also been shown to be involved in the regulation of neurodegenerative diseases. Ncrna00185 has been shown to play a role in the regulation of gene expression in neurodegenerative diseases, including Alzheimer's disease and Parkinson's disease.

In addition to its role in neurodegenerative diseases, Ncrna00185 has also been shown to be involved in the regulation of autoimmune diseases. Ncrna00185 has been shown to play a role in the regulation of gene expression in autoimmune diseases, including rheumatoid arthritis and multiple sclerosis.

Conclusion

In conclusion, Ncrna00185 is a promising RNA molecule that has a unique structure and biology. Ncrna00185 has been shown to play a role in various biological processes, including cell growth, apoptosis, and

Protein Name: Non-protein Coding RNA 185

The "Non-protein coding RNA 185 Target / Biomarker Review Report" is a customizable review of hundreds up to thousends of related scientific research literature by AI technology, covering specific information about Non-protein coding RNA 185 comprehensively, including but not limited to:
•   general information;
•   protein structure and compound binding;
•   protein biological mechanisms;
•   its importance;
•   the target screening and validation;
•   expression level;
•   disease relevance;
•   drug resistance;
•   related combination drugs;
•   pharmacochemistry experiments;
•   related patent analysis;
•   advantages and risks of development, etc.
The report is helpful for project application, drug molecule design, research progress updates, publication of research papers, patent applications, etc. If you are interested to get a full version of this report, please feel free to contact us at BD@silexon.ai

More Common Targets